Fermion & Simcere Partner to Develop SSTR4 Pain Treatment Asset FZ002-037

Guangzhou Fermion Technology Co., Ltd., a clinical-stage, AI-driven biotech company, and Simcere Pharmaceutical Group Limited, a pharmaceutical company, have announced a partnership to develop a clinical-stage pain treatment asset, FZ002-037, targeting SSTR4.

FZ002-037 is a highly selective oral small-molecule SSTR4 agonist developed by Fermion. Preclinical studies indicate that the drug primarily provides peripheral analgesia without central side effects or addiction risks, making it a promising option for patients requiring long-term pain management. It is the first domestically developed SSTR4 agonist in China and the second globally to reach the clinical stage. The drug has completed phase I clinical trials in China, with phase II studies for diabetic peripheral neuropathy set to begin soon. Potential applications extend to various chronic and acute pain conditions.

Dr. Deco Deng, founder of Fermion, stated: ""We are delighted to partner with Simcere, a leading pharmaceutical company. As the first domestically developed and the world's second high-selectivity SSTR4 agonist to enter the clinical stage, FZ002-037 holds great promise. By leveraging Simcere's strong development and commercialization capabilities, we are confident in accelerating its progress to provide better treatment options for patients suffering from pain.""

Zhou Gaobo, chief investment officer of Simcere, added: ""Pain significantly affects patients' quality of life and remains a major unmet clinical need. Addressing these 'clinical pain points' has always been a core mission for Simcere. We look forward to collaborating with innovative partners like Fermion to deliver more effective and safer pain therapies to patients as quickly as possible.""

Under the agreement, Simcere will gain exclusive rights to develop and commercialize FZ002-037 in Greater China (Mainland China, Hong Kong, Macau, and Taiwan). Fermion will receive an upfront payment, milestone payments, and tiered royalties based on future sales.

FZ002-037 is a phase II-ready non-opioid pain treatment that acts as an oral SSTR4 agonist. It is the first SSTR4 agonist to enter clinical trials in China and the second globally. The drug demonstrates excellent selectivity, with a double-digit pM EC50 and strong efficacy in multiple chronic and acute pain models. Phase I studies revealed a favourable safety profile, with no reported CNS or gastrointestinal adverse events, and an attractive PK profile (potential once-daily dosing). These characteristics highlight its potential as a breakthrough therapeutic option to address the unmet need for effective, non-addictive pain relief.

Fermion is a clinical-stage, AI-driven biotech company founded in 2019. The company focuses on developing differentiated best-in-class (BIC) and first-in-class (FIC) products in the central nervous system (CNS) and autoimmune fields.

Simcere Pharmaceutical Group Limited is a pharmaceutical company driven by innovative R&D, and houses a ""State Key Laboratory of Neurology and Oncology Drug Development.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!